Recent study has given hope of developing new range of drugs to treat Alzheimer's disease. Research team from the United States, South Korea and France has found that class of drugs targeting the N60 section of a protein called "RanBP9" would be able to cure Alzheimer's disease.

According to statistics of the U.S. Centers for Disease Control and Prevention, nearly 5 million Americans suffer from Alzheimer's disease, the most common form of dementia among older adults. It makes a person dependent on others as the patient is not able to carry out daily activities.

In the recent study, researchers studied extracts from brains with Alzheimer's disease and age-matched healthy individuals without the disease. They found that the N60 section of RanBP9 was increased in Alzheimer's brain as compared to the brains of people without the disease.

Research team believes that the N60 section of that protein is linked with the elevated levels of known Alzheimer's pathogen amyloid beta plaques.

Researchers said that brain cells that expressed the N60 part of the protein produced five times the amount of amyloid beta plaques that normal cells produce.

David Kang, assistant professor of neurosciences at the University of California, San Diego said: "Our study suggests that targeting RanBP9 expression and/or N60 fragment generation may lead to novel strategies to combat this devastating disease."